drugset / Trial / NCT02252536
HORIZANT (Gabapentin Enacarbil Extended-Release Tablets) for the Treatment of Alcohol Use Disorder
Phase 2
Completed
346 enrolled
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Arbor Pharmaceuticals, Inc. · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to determine whether gabapentin enacarbil is effective in the treatment of problems with alcohol.
Timeline
- Start
- 2015-06
- Primary completion
- 2017-03
- Completion
- 2017-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | gabapentin enacarbil | Small molecule | 600 mg | — |